Success Metrics

Clinical Success Rate

56.3%

Based on 9 completed trials

Completion Rate

56%(9/16)

Active Trials

0(0%)

Results Posted

0%(0 trials)

Terminated

7(41%)

Phase Distribution

Ph phase_3

29%

Ph phase_4

71%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution17 total trials

Phase 3Large-scale testing

5(29.4%)

Phase 4Post-market surveillance

12(70.6%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

52.9%

9 of 17 finished

Non-Completion Rate

47.1%

8 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(9)

Terminated(8)

Detailed Status

Completed9

Terminated7

Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

56.3%

Most Advanced

Phase 4

Trials by Phase

Phase 35 (29.4%)

Phase 412 (70.6%)

Trials by Status

completed953%

terminated741%

withdrawn16%

Recent Activity

0 active trials

Showing 5 of 17

completedphase_3

Controlled Trial: 5-day Course of Telithromycin Versus Doxycycline for the Treatment of Mild to Moderate Scrub Typhus

NCT00351182

withdrawnphase_4

Outpatient Registry Trial of Respiratory Tract Infections in Adults

NCT00245453

completedphase_3

AMS VS MOXI Ketek vs Avelox in AMS

NCT00537563

completedphase_4

Telithromycin, Treating Adult Outpatients With Mild to Moderate Community-acquired Pneumonia (CAP) in High Bacterial Resistance Areas

NCT00538018

completedphase_4

Telithromycin: in the Treatment of Acute Exacerbation of Chronic Bronchitis in Adult Outpatients With COPD

NCT00538148

View all 17 trials

Clinical Trials (17)

Showing 17 of 17 trials

NCT00351182Phase 3

Controlled Trial: 5-day Course of Telithromycin Versus Doxycycline for the Treatment of Mild to Moderate Scrub Typhus

Completed

NCT00245453Phase 4

Outpatient Registry Trial of Respiratory Tract Infections in Adults

Withdrawn

NCT00537563Phase 3

AMS VS MOXI Ketek vs Avelox in AMS

Completed

NCT00538018Phase 4

Telithromycin, Treating Adult Outpatients With Mild to Moderate Community-acquired Pneumonia (CAP) in High Bacterial Resistance Areas

Completed

NCT00538148Phase 4

Telithromycin: in the Treatment of Acute Exacerbation of Chronic Bronchitis in Adult Outpatients With COPD

Completed

NCT00132938Phase 4

PERSPECTIVE: Telithromycin - Acute Exacerbation of Chronic Bronchitis

Completed

NCT00237445Phase 4

Study Comparing the Clinical Efficacy and Health Outcomes of Outpatients With Mild to Moderate Community-Acquired Pneumonia (CAP) Treated With Either Telithromycin Once Daily for 7 Days, or Azithromycin Once Daily for 5 Days

Terminated

NCT00288223Phase 4

Telithromycin in Acute Exacerbation of Chronic Bronchitis

Terminated

NCT00174694Phase 4

CHOOSE : Telithromycin, Acute Bacterial Sinusitis

Completed

NCT00261105Phase 4

Telithromycin in Respiratory Tract Infections

Completed

NCT00273520Phase 3

TELICAST : Telithromycin in Acute Exacerbations of Asthma

Completed

NCT00132951Phase 4

KEYS: Study Comparing Clinical Health Outcomes of Telithromycin Versus Azithromycin in Outpatients With Community-acquired Lower Respiratory Tract Infections

Terminated

NCT00315003Phase 3

TELI COM - Telithromycin in Children With Otitis Media

Terminated

NCT00315549Phase 3

TELI TAD - Telithromycin in Tonsillitis in Adolescents and Adults

Terminated

NCT00315601Phase 4

Intrapulmonary Pharmacokinetics of Antibiotics

Terminated

NCT00546676Phase 4

Ketek in CAP / AECB in Ambulatory Adult Patients